Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun;13(6):e1057-e1071.
doi: 10.1016/S2214-109X(25)00054-3. Epub 2025 Apr 22.

Aetiologies, neuroradiological features, and risk factors for mortality and long-term neurosequelae of febrile coma in Malawian children: a prospective cohort study

Affiliations
Free article

Aetiologies, neuroradiological features, and risk factors for mortality and long-term neurosequelae of febrile coma in Malawian children: a prospective cohort study

Stephen T J Ray et al. Lancet Glob Health. 2025 Jun.
Free article

Erratum in

Abstract

Background: Children in febrile coma in Africa are frequently hospitalised, with poorer outcomes than those in high-income settings. Cerebral malaria is historically the most common cause of febrile coma. Due to limited diagnostic and radiological resources and a decrease in malaria prevalence, there might be under-recognition of non-malarial coma. However, prospective data are scarce. We aimed to determine causes, neuroradiological features, risk factors for mortality, and neurosequelae of children in febrile coma in Malawi.

Methods: In this prospective cohort study, we enrolled children in a coma (Blantyre Coma Scale score ≤2) who were aged between 3 months and 15 years at Queen Elizabeth Central Hospital, Blantyre, Malawi. We used pathogen-specific PCR analysis of blood and cerebrospinal fluid for 15 pathogens including Streptococcus pneumoniae, Neisseria meningitidis, Haemophilus influenzae, Salmonella spp, non-typhoidal Salmonella, Salmonella enterica serotype Typhi (S Typhi), Klebsiella spp, Escherichia coli, Mycobacterium tuberculosis (also using GeneXpert), Streptococcus agalactiae, herpes simplex virus (types 1 and 2), varicella zoster virus, cytomegalovirus, enteroviruses, and SARS-CoV-2; microscopy for malaria; admission brain MRI to enhance the diagnosis of cause and identify brain injury, swelling, and any other complications; and electroencephalography tracings were used identify subclinical seizures or non-convulsive status epilepticus. Assessment of malarial retinopathy was performed by a trained ophthalmologist. We used regression models to estimate risk factors for (and the difference in) 30-day mortality and 180-day neurosequelae (outcome assessed in-person) between children with non-malarial coma and cerebral malaria.

Findings: Between Jan 31, 2018, and June 30, 2021, we recruited 352 children with febrile coma. Cerebral malaria was the most common cause (in 231 [66%] of 352 children). Pathogenic diagnosis was possible in 289 (82%) of 352 children. Co-infection was identified in 63 (27%) of 231 children with cerebral malaria, of which 49 (78%) were bacterial. The most common non-malarial causes of coma were meningitis (48 [14%] of 352 children) and encephalitis (24 [7%] of 352); 32 (9%) cases had an unknown cause. Compared with standard cultures, PCR significantly increased pathogen diagnosis (p<0·0001), with the highest yield in patients with meningitis (seven [15%] of 48 vs 30 [63%] of 48). S pneumoniae (n=44) and non-typhoidal salmonella or S Typhi (n=24) were the most frequently detected bacterial pathogens. Brain parenchymal abnormalities were identified on MRI in most children with febrile coma (165 [92%] of 178), and were significantly more common in children with non-malarial coma (68 [100%] of 68]) than cerebral malaria (98 [89%] of 110; p<0·0001). Overall, at 30 days after discharge, death (69 [21%] of 323) or any neurological impairment (163 [50%] of 323) were common, but poorer long-term outcomes were more frequent following non-malarial coma than cerebral malaria (death at 30 days: 32 [28%] of 114 vs 37 [18%] of 209, p=0·029; severe neurological impairment at 180 days: 19 [17%] of 114 vs 15 [7%] of 209, p=0·0079). Children who had cerebral malaria with CNS co-infection had higher mortality (ten [37%] of 27) than those with cerebral malaria alone (19 [12%] of 154, p=0·0033).

Interpretation: Despite malaria control efforts, cerebral malaria remains the most common cause of febrile coma in Malawi. However, non-malarial coma causes a greater disease burden (death and disability), and a higher case-fatality rate was observed in non-malarial coma and cerebral malaria with non-malarial co-infection than cerebral malaria alone. To adequately treat severe invasive bacterial infections, that are frequently not detected in routine clinical practice, commencing empirical antimicrobials in all children in febrile coma, including those with cerebral malaria, could and should be rapidly implemented across Africa and must be considered. The study highlights the value of molecular diagnostics and imaging to guide diagnosis. The frequent findings of brain abnormalities from imaging at admission emphasises the need for earlier escalation of children with febrile coma to specialist care. Further work is needed to develop feasible molecular and radiological diagnostics for their successful deployment across the continent. Implementation of these methods could improve diagnosis and outcomes for children with febrile coma in Africa.

Funding: Wellcome Trust TRANSLATIONS: For the Chichewa, French and Portuguese translations of the abstract see Supplementary Materials section.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests DGL, MYRH, CA, and SBG are supported by The Wellcome core award (award number 206545/Z/17/Z) to Malawi–Liverpool Wellcome Trust. STJR and MN are also supported by Wellcome to conduct paediatric infectious diseases research (203919/Z/16/Z). STJR is also supported by a Thrasher child health early career award, Academy of Medical Sciences starter grant, and European Society of Paediatric Infectious Diseases Society diagnostic grant; is a Centre for Human Genetics Well Institute Olink-48 grant prize winner and Early Career Research committee member, both at The University of Oxford. MN is also supported by Roche Diagnostics for a Baby and Mother Biomarkers of Infection study, Liverpool School of Tropical Medicine as a Clinical Fellow for The DIAMONDS Research Consortia, and FIND Diagnostics for a Literature review on the Utility of CRP testing in primary care in low-resource settings for supporting patient management and antibiotic stewardship; is an invited speaker at The Paediatric Infectious Diseases Games; and is Deputy Convenor, Research Co-Lead, and Winter Meeting Lead for the Royal College of Paediatrics and Child Health International Child Health Group. MJG is supported to conduct neuroscience and infection research internationally by the Medical Research Council (MRC) Newton Fund (MR/S019960/1), MRC Development Pathway Funding Scheme (MR/R015406/1) and National Institute for Health and Care Research (NIHR; 153195 17/60/67, 126156 17/63/11, and 200907). CAM is a UKRI MRC Future Leaders Fellow (MR/V025856/1). TS is supported by the NIHR Health Protection Research Unit in Emerging and Zoonotic Infections (IS-HPU-1112–10117), NIHR Global Health Research Group on Brain Infections (17/63/110), and The Pandemic Institute, Liverpool, UK; receives royalties from Oxford University Press, Liverpool University Press, Cambridge University, and Elsevier for published books he has written on brain infections; co-chaired the Medicines and Healthcare Products Regulatory Agency (MHRA) Expert Working Group on COVID-19 vaccines between 2020 and 2023; was a member of the COVID-19 Vaccines Benefit Risk Expert working group, for the Commission on Human Medicines (CHM) committee of the MHRA between 2020 and 2023; is a committee member of the Wellcome Trust Pathogen Biology and Disease Transmission Discovery Advisory Group; was a member of the MRC's Infections and Immunity Board between 2018 and 2022; sat on the Research Excellence Framework Panel between 2021 and 2022; and was on the Data Safety Monitoring Committee of the GSK Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Children (ChAd3 EBO-Z) vaccine (GSK3390107A). BDM is supported for COVID-19 neuroscience research by UK Research and Innovation (UKRI; MR/V03605X/1) and the MRC (MR/V03605X/1); and for additional neurological inflammation due to viral infection research by grants from the MRC and UKRI (MR/V007181/1), MRC (MR/T028750/1), and the Wellcome Trust (ISSF201902/3). TT is supported by a research grant from the National Institutes of Health (NIH); is the President-Elect for the American Society of Tropical Medicine and Hygiene and is a member of the Malaria Advisory Council for Novartis. GLB is supported by two active and two recent research grants from NIH; consults on educational materials for Neurotorium, and TempTraq and similar devices at Blue Spark Technologies; lectures for The University of Calgary; participates on an advisory board for the BRIDGE clinical trial; and is on the editorial board of the Lancet Neurology, Neurotorium, and Zambian League against Epilepsy. RD is a consulting radiologist for a separate infection project for the University of Oxford; is an honorary teaching fellow at The Liverpool School of Tropical Medicine; is training programme advisor at the British Society of Head and Neck Imaging; examiner for The Royal College of Radiologists; and trustee and educational lead for Worldwide Radiology. STJR, BDM, and TS are members of the Encephalitis International Scientific Advisory Panel; BDM is Scientific Chair and TS is President. All other authors declare no competing interests.

Similar articles

Cited by

LinkOut - more resources